SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Increase in Short Interest

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 12,220,000 shares, a growth of 39.5% from the May 15th total of 8,760,000 shares. Based on an average trading volume of 1,910,000 shares, the short-interest ratio is currently 6.4 days. Approximately 17.6% of the company's stock are short sold.

SELLAS Life Sciences Group Price Performance

SELLAS Life Sciences Group stock traded down $0.05 during midday trading on Monday, reaching $1.61. 1,753,138 shares of the company traded hands, compared to its average volume of 1,590,473. The firm has a market capitalization of $160.64 million, a price-to-earnings ratio of -2.33 and a beta of 2.25. The business has a 50 day moving average of $1.53 and a two-hundred day moving average of $1.27. SELLAS Life Sciences Group has a 12 month low of $0.77 and a 12 month high of $2.12.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. As a group, equities analysts forecast that SELLAS Life Sciences Group will post -0.57 EPS for the current year.

Insider Buying and Selling

In related news, Director Jane Wasman purchased 20,000 shares of SELLAS Life Sciences Group stock in a transaction dated Friday, May 30th. The stock was purchased at an average cost of $1.69 per share, for a total transaction of $33,800.00. Following the completion of the acquisition, the director now directly owns 30,400 shares of the company's stock, valued at $51,376. The trade was a 192.31% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Large investors have recently made changes to their positions in the company. Anson Funds Management LP grew its stake in shares of SELLAS Life Sciences Group by 535.7% during the first quarter. Anson Funds Management LP now owns 7,579,095 shares of the company's stock valued at $8,185,000 after buying an additional 6,386,829 shares during the last quarter. Geode Capital Management LLC raised its position in shares of SELLAS Life Sciences Group by 21.2% in the 4th quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock valued at $763,000 after purchasing an additional 128,355 shares during the last quarter. Brooklyn FI LLC acquired a new position in shares of SELLAS Life Sciences Group in the 4th quarter valued at $677,000. Opus Capital Group LLC increased its holdings in SELLAS Life Sciences Group by 5.5% in the 4th quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock worth $248,000 after buying an additional 12,400 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of SELLAS Life Sciences Group by 33.6% in the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after buying an additional 33,878 shares during the last quarter. 17.38% of the stock is owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.